Table 1.
Current COVID-19 prospective trials on glucose-lowering interventions in patients with T2DM
| Clinical trial numbera | Drug tested | Placebo controlled | N |
|---|---|---|---|
| 04510194 | Metformin | Yes | 750 |
| 04625985 | Yes | 20 | |
| 04727424 | Yes (metformin + 2 other IDs) | 2,724 | |
| 04604223 | Pioglitazone | Yes | 1,506 |
| 04535700 | No | 76 | |
| 04473274 | No | 20 | |
| 04542213 | Linagliptin | No, linaglitpin + insulin vs insulin | 70 |
| 04371978 | No, linaglitpin + insulin vs insulin | 100 | |
| 04393246 | Dapagliflozine | No, dapagliflozine + 2 other IDs vs SOC | 1,407 |
| 04350593 | Yes | 1,250 |
The full version of this table, including inclusion criteria and primary outcomes, is available in the supplementary information. aActively recruiting or completed trials registered on Clinicaltrial.gov (accessed on 13 April 2021). COVID-19, coronavirus disease 2019; ID, investigation drug; SOC, standard of care; T2DM, type 2 diabetes mellitus.